Syros Pharmaceuticals Inc (NASDAQ: SYRS) kicked off on Monday, up 19.71% from the previous trading day, before settling in for the closing price of $0.21. Over the past 52 weeks, SYRS has traded in a range of $0.18-$8.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 128.79%. While this was happening, its average annual earnings per share was recorded 72.86%. With a float of $17.43 million, this company’s outstanding shares have now reached $26.83 million.
Considering the fact that the conglomerate employs 68 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is -228.76%, operating margin of -28892.23%, and the pretax margin is -25340.67%.
Syros Pharmaceuticals Inc (SYRS) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Syros Pharmaceuticals Inc is 35.03%, while institutional ownership is 36.36%. The most recent insider transaction that took place on Dec 30 ’24, was worth 2,306. Before that another transaction happened on Dec 27 ’24, when Company’s Affiliate proposed sale 1,331,624 for $0.21, making the entire transaction worth $279,641.
Syros Pharmaceuticals Inc (SYRS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.7 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 72.86% per share during the next fiscal year.
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Trading Performance Indicators
Take a look at Syros Pharmaceuticals Inc’s (SYRS) current performance indicators. Last quarter, stock had a quick ratio of 2.25. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.03, a number that is poised to hit -0.72 in the next quarter and is forecasted to reach -2.29 in one year’s time.
Technical Analysis of Syros Pharmaceuticals Inc (SYRS)
Compared to the last year’s volume of 2.42 million, its volume of 5.2 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 52.02%. Additionally, its Average True Range was 0.07.
During the past 100 days, Syros Pharmaceuticals Inc’s (SYRS) raw stochastic average was set at 1.33%, which indicates a significant decrease from 50.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 106.69% in the past 14 days, which was lower than the 376.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0250, while its 200-day Moving Average is $3.4930. Nevertheless, the first resistance level for the watch stands at $0.3064 in the near term. At $0.3625, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.4151. If the price goes on to break the first support level at $0.1977, it is likely to go to the next support level at $0.1451. Should the price break the second support level, the third support level stands at $0.0890.
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Key Stats
The company with the Market Capitalisation of 6.71 million has total of 26,832K Shares Outstanding. Its annual sales at the moment are 9,940 K in contrast with the sum of -164,570 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -6,400 K.
